Biotron Ltd (BIT) - Total Assets
Based on the latest financial reports, Biotron Ltd (BIT) holds total assets worth AU$3.86 Million AUD (≈ $2.73 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biotron Ltd - Total Assets Trend (2000–2025)
This chart illustrates how Biotron Ltd's total assets have evolved over time, based on quarterly financial data. Also see how much is Biotron Ltd worth for the company's overall valuation and market capitalisation.
Biotron Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Biotron Ltd's total assets of AU$3.86 Million consist of 97.5% current assets and 2.6% non-current assets. Review BIT total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 95.0% |
| Accounts Receivable | AU$7.08K | 0.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$4.59K | 0.5% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Biotron Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Biotron Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biotron Ltd's current assets represent 97.5% of total assets in 2025, an increase from 26.1% in 2000.
- Cash Position: Cash and equivalents constituted 95.0% of total assets in 2025, up from 26.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 73.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Biotron Ltd Competitors by Total Assets
Key competitors of Biotron Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
Biotron Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.47 | 1.83 | 7.79 |
| Quick Ratio | 1.47 | 1.83 | 7.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$544.56K | AU$417.93K | AU$4.56 Million |
Biotron Ltd - Advanced Valuation Insights
This section examines the relationship between Biotron Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.06 |
| Latest Market Cap to Assets Ratio | 4.02 |
| Asset Growth Rate (YoY) | 98.7% |
| Total Assets | AU$980.40K |
| Market Capitalization | $3.94 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biotron Ltd's assets at a significant premium (4.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Biotron Ltd's assets grew by 98.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biotron Ltd (2000–2025)
The table below shows the annual total assets of Biotron Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$980.40K ≈ $693.70K |
+98.67% |
| 2024-06-30 | AU$493.48K ≈ $349.17K |
-88.07% |
| 2023-06-30 | AU$4.14 Million ≈ $2.93 Million |
+116.95% |
| 2022-06-30 | AU$1.91 Million ≈ $1.35 Million |
-55.94% |
| 2021-06-30 | AU$4.33 Million ≈ $3.06 Million |
-44.72% |
| 2020-06-30 | AU$7.83 Million ≈ $5.54 Million |
+33.62% |
| 2019-06-30 | AU$5.86 Million ≈ $4.14 Million |
+261.72% |
| 2018-06-30 | AU$1.62 Million ≈ $1.15 Million |
-21.38% |
| 2017-06-30 | AU$2.06 Million ≈ $1.46 Million |
-40.87% |
| 2016-06-30 | AU$3.48 Million ≈ $2.46 Million |
-24.54% |
| 2015-06-30 | AU$4.62 Million ≈ $3.27 Million |
+147.66% |
| 2014-06-30 | AU$1.86 Million ≈ $1.32 Million |
-61.70% |
| 2013-06-30 | AU$4.87 Million ≈ $3.44 Million |
-42.49% |
| 2012-06-30 | AU$8.46 Million ≈ $5.99 Million |
+219.96% |
| 2011-06-30 | AU$2.64 Million ≈ $1.87 Million |
+42.35% |
| 2010-06-30 | AU$1.86 Million ≈ $1.31 Million |
+74.64% |
| 2009-06-30 | AU$1.06 Million ≈ $752.73K |
-53.08% |
| 2008-06-30 | AU$2.27 Million ≈ $1.60 Million |
+49.26% |
| 2007-06-30 | AU$1.52 Million ≈ $1.07 Million |
-68.45% |
| 2006-06-30 | AU$4.81 Million ≈ $3.41 Million |
+98.22% |
| 2005-06-30 | AU$2.43 Million ≈ $1.72 Million |
-21.89% |
| 2004-06-30 | AU$3.11 Million ≈ $2.20 Million |
-47.38% |
| 2003-06-30 | AU$5.91 Million ≈ $4.18 Million |
-31.55% |
| 2002-06-30 | AU$8.63 Million ≈ $6.11 Million |
-15.30% |
| 2001-06-30 | AU$10.19 Million ≈ $7.21 Million |
-75.86% |
| 2000-06-30 | AU$42.22 Million ≈ $29.87 Million |
-- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.